← Back to Clinical Trials
Recruiting Phase 2 NCT06790082

NCT06790082 The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06790082
Status Recruiting
Phase Phase 2
Sponsor Aalborg University Hospital
Condition Pleural Mesothelioma
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2025-01-29
Primary Completion 2027-04-30

Trial Parameters

Condition Pleural Mesothelioma
Sponsor Aalborg University Hospital
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 70
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-01-29
Completion 2027-04-30
Interventions
[68Ga]Ga-FAPI-46 PET/CT

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Seventy (N=70) patients with suspected pleural mesothelioma (PM) lesions referred to pleural biopsy will be recruited, and undergo an additional FAPI PET/CT at primary staging. The FAPI PET/CT results will be compared to conventional imaging (including FDG PET/CT). The diagnostic accuracy will be determined with histopathology as reference standard. For patients undergoing anticancer treatment (chemotherapy, immunotherapy, other treatment), an additional FAPI PET/CT and an additional FDG PET/CT will be conducted after the study subjects have completed 2-3 series of anticancer treatment. The feasabilitiy of FAPI PET/CT in response evaluation will be investigated. All study specific analyzes will be blinded and will not influence the patient management / treatment.

Eligibility Criteria

Inclusion Criteria: * Patients with pleural lesions suspicious of pleural mesothelioma and referred to pleural biopsy. * Undergone/undergoing FDG PET/CT as part of the diagnostic workup of a suspicious PM lesion. * Considered physically and mentally able to participate in the research project. * Understands the study subject information and able to consent to project participation. * 18-years or older Exclusion Criteria: * Patients with an imminent need for surgery or in an emergency * Known concurrent other malignancy with active treatment within the last 1 year; non-melanoma skin cancer and cervical cancer in situ are exempt. * Pregnant or breastfeeding women. * Fertile women (women of childbearing potential) who could - theoretically - be pregnant (i.e., unknown pregnancy status). Fertile women will be tested for pregnancy (by urine humane choriogonadotropin (HCG) or serum HCG) within 48h before FAPI PET/CTs, both at primary staging and restaging. Study subjects can participate in t

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology